Dicerna to Report Fourth Quarter and Full Year 2016 Financial Results and Host Conference Call on March 30, 2017
March 23 2017 - 4:05PM
Business Wire
Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA), a leading developer
of investigational ribonucleic acid interference (RNAi)
therapeutics, today announced that the Company will release its
fourth quarter and full year 2016 financial results after market
close on Thursday, March 30, 2017.
Management will host a conference call at 4:30 p.m. ET that day
to discuss the Company's financial results and provide a general
business update. The conference call will be webcast live via the
Internet and will be available on the “Investors & Media”
section of the Dicerna website, www.dicerna.com. The webcast will
also be archived on the Company's website.
The call can also be accessed by dialing (855) 453-3834 or (484)
756-4306 (international), and referencing conference ID 70365614
prior to the start of the call. After the conference call, a replay
will be available until April 6, 2017. To access the replay, please
dial (855) 859-2056 or (404) 537-3406, and refer to conference ID
70365614.
About Dicerna Pharmaceuticals, Inc.
Dicerna Pharmaceuticals, Inc., is a biopharmaceutical company
focused on the discovery and development of innovative RNAi-based
therapeutics for diseases involving the liver, including rare
diseases, chronic liver diseases, cardiovascular diseases, and
viral infectious diseases. The Company is leveraging its
proprietary GalXC™ RNAi technology platform to build a broad
pipeline in these core therapeutic areas, focusing on target genes
where connections between target gene and diseases are well
understood and documented. The Company intends to discover, develop
and commercialize novel therapeutics either on its own or in
collaboration with pharmaceutical partners. For more information,
please visit www.dicerna.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170323005269/en/
Investors:Rx Communications GroupPaula Schwartz,
917-322-2216pschwartz@rxir.comorMedia:SmithSolveAlex Van
Rees, 973-442-1555 ext. 111alex.vanrees@smithsolve.com
Dicerna Pharmaceuticals (NASDAQ:DRNA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Dicerna Pharmaceuticals (NASDAQ:DRNA)
Historical Stock Chart
From Apr 2023 to Apr 2024
